The Baculoviral IAP Repeat Containing Protein 2 pipeline drugs market research report outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Baculoviral IAP Repeat Containing Protein 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Infectious Disease which include the indications Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, and Human Immunodeficiency Virus (HIV) Infections (AIDS). It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Baculoviral IAP Repeat Containing Protein 2 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Phase I stages are 1, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Baculoviral IAP Repeat Containing Protein 2 overview
Baculoviral IAP Repeat-Containing Protein 2, commonly denoted as BIRC2, is a cellular protein associated with the inhibitor of apoptosis (IAP) family. This protein family is recognized for its function in governing cell survival and thwarting programmed cell death, also known as apoptosis. BIRC2 serves as an E3 ubiquitin-protein ligase, impacting the regulation of NF-kappa-B signaling. It exerts control over both the canonical and non-canonical NF-kappa-B signaling pathways but with contrasting effects: it functions as a positive regulator of the canonical pathway while suppressing the constitutive activation of the non-canonical NF-kappa-B signaling.
For a complete picture of Baculoviral IAP Repeat Containing Protein 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
